In June 2025, 337 ton of toxic waste from the Union Carbide factory in Bhopal finally left from the city in 12 trucks and arrived at the Pithampura industrial area. The waste was carried in spill-free trucks, but the impact of this toxic waste and the toxic gas on people, still spills today.

As we observe the National Pollution Control Day today, which commemorates the victims of the 1984 Bhopal Gas Tragedy, we also look back onto how its spill on human lives.

Also Read: Trump MRI Results Released: Heart and Abdomen Scan ‘Perfectly Normal’, White House Says

What Happened On December 2 and 3, 1984?

Between December 2 and 3, around midnight, in 1984, there was a massive leak of a poisonous chemical methyl isocyanate (MIC) from a Union Carbide pesticide plant that took thousand lives, and maimed a thousand more, leaving many, even four decades later, impacted.

As per the 1992 study by R Dhara, the gas leak caused chronic inflammatory damage to the eyes and lungs, which was also the main cause of morbidity. Reproductive health problems in form of increased spontaneous abortions and psychological problems were also reported.

The leak was called world's worst industrial disaster. Around 40 ton of toxic methyl isocyanate gas was released into air, and killed more than 3,000 people.

Also Read: Scromiting: What Is This Severe Vomiting Syndrome Linked To Long-Term Cannabis Use

Those Who Are Still Affected

The toxic waste which had been lying till June this year, as per surveys, contain 6 of the persistent organic pollutants that are banned by the United Nations for their highly poisonous impacts on the environment and human health.

As per the data by the Sambhavna Trust, even after 3 decades, the mortality rate for gas-exposed victims is still 28% higher than the average. The survivors are twice as likely to die of cancers, lung diseases, and tuberculosis. They are also three times as likely to die from kidney diseases and 63% more likely to have illnesses. The data also showed that a 25% of the survivors who had been exposed to the gas were under-active thyroid and can have long-term health impacts.

The explosion also had adverse effects on women, babies, and caused a high rate of infertility, stillbirths, abortions, early menopause and irregularities in menstrual cycles. The Guardian reported that many women left their husbands as they believed "not to be capable of fulfilling the familial duties expected of them".

The Chingari Children's Centre which was established for those born with disabilities due to the gas tragedy registered over 1,000 children. Many of these kids were affected by cerebral palsy, muscular dystrophy, autism, intellectual disabilities, and severe learning difficulties.

A study by the Indian Council for Medical Research (ICMR), found that still 9% of babies who were born between 2016-17 had birth defects. These babies were born to mothers who had been exposed to gas. The Guardian reports that the "study was subsequently discredited by the ICMR, who ordered it not to be published or disclosed."

The Leak That Leaks Even Today

Last year, in September, survivors of the tragedy also visited Harvard TH Chan School of Public Health and shared their stories. The survivors included two women who were children when the gas leak happened, Farhat Jahan and Bati Bai Rajak. They shared that the disaster still continues to leave its impact on the new generation.

A 2023 study published in journal BMJ One also revealed that even after four decades of the tragedy, future generations are afflicted by disabilities and cancer. The study also noted a decline in male births a year after the tragedy, impacting around 100km radius around Bhopal.

Other health conditions include respiratory, neurological, musculoskeletal, ophthalmic, and endocrine issues. The impact also resulted in a 4-fold increase in miscarriages and a higher risk of stillbirth. Researchers from the University of California San Diego also noted that reproductive health impacts could trickle town to future generations, which could be seen even today.

Gordon McCord from the School of Global Policy and Strategy at UC San Diego and the author of the study said that male fetuses are more suspectable to adverse shocks including smog, disease, natural disasters and stressful events during pregnancy. This was reported in media outlet Down To Earth.

Studies also found that men born in 1985 within the 100 km of Bhopal had eight-fold increased risk of cancer.

Another study which analyzed the survivors from 1985 to 1994, titled Health Effects of the Toxic Gas Leak from the Union Carbide Methyl Isocyanate Plant in Bhopal noted for genetic risk of pregnancy outcome in women who were exposed to the toxic gas. The abortion rate was 523 per 1000, immediately after the tragedy. The study also found that infants were born with congenital malformations.

Bhopal gas leak tragedy paved way for a safer workspace and lead to the many laws which aims to protect the survivors, their rights, and also holds the companies accountable for the damage. However, despite this, many survivors still continue to live with chronic pain, diseases, and scarred memories from the tragedy.

This day observed as the National Pollution Control Day is a reminder to why environmental safety is key to health safety, and must alarm the nation for the air pollution situation that continues to worsen by every passing day.

Eli Lilly's experimental weight-loss drug retatrutide, being referred to as ‘Godzilla’, continues to outperform its rivals like Ozempic.

According to a recent head-to-head Phase 3 clinical trial involving adults with type 2 diabetes, it delivered more than twice the average weight loss achieved with Ozempic.

Ozempic Vs Retatrutide

Participants who took the highest dose of retatrutide lost an average of 20.9% of their body weight over 80 weeks, compared to 9.4% among those receiving Ozempic's highest approved dose for type 2 diabetes.

The trial, called TRANSCEND-T2D-2, involved more than 1,000 adults with type 2 diabetes. It compared once-weekly injections of retatrutide at doses of 9 mg and 12 mg with semaglutide, the active ingredient in Ozempic, at 2 mg.

At the end of 80 weeks, participants taking retatrutide 9 mg lost an average of 44.3 pounds (20.1 kg), while those receiving the 12 mg dose lost 47.4 pounds (21.5 kg). The Ozempic group lost an average of 20.9 pounds (9.5 kg).

The findings mark the first Phase 3 head-to-head comparison of retatrutide with another medicine in this class.

Also read: ‘Godzilla’ Drug Retatrutide Reverses Sleep Apnea In 1 In 4 Diabetes Patients

Retatrutide Also Improved Blood Sugar

The trial found that retatrutide also resulted in produced greater reductions in HbA1c, a measure of average blood glucose over approximately three months.

At 80 weeks, participants taking either dose of retatrutide recorded an average HbA1c reduction of 2.2%, compared to 1.8 % among those receiving Ozempic.

The experimental drug also resulted in greater improvements in cardiovascular risk factors like non-HDL cholesterol, triglycerides and systolic blood pressure.

Also read: Could GLP-1 Drugs Help Prevent Rupture Of Abdominal Aortic Aneurysm? Study Finds 46% Reduction In Risk

Side Effects Of Retatrutide

The most commonly reported side effects of retatrutide were gastrointestinal symptoms like diarrhoea, nausea, constipation, vomiting and indigestion.

Diarrhoea was reported in 28.3% of participants receiving the 9 mg dose and 32.7% receiving 12 mg, compared to 26.4% in the Ozempic group. Nausea occurred in 21.2%, 23.8% and 21.3% of participants, respectively.

Researchers also reported a higher incidence of dysesthesia, an abnormal sensation that can include tingling, burning or skin sensitivity, among participants taking retatrutide.

Treatment discontinuation because of side effects occurred in 4.8% of the 9 mg group and 7.9% of the 12 mg group, compared to 2.7% of the Ozempic group.

More About Retatrutide

Retatrutide is a once-weekly injectable drug that targets three hormone receptors involved in regulating appetite, blood sugar and metabolism. They are GLP-1, GIP and glucagon.

GLP-1 helps regulate appetite and blood sugar while slowing the process of stomach emptying. GIP also plays a role in glucose regulation and insulin release. Glucagon is involved in controlling blood glucose and energy metabolism.

Ozempic, manufactured by Novo Nordisk, acts on the GLP-1 receptor. Eli Lilly's Mounjaro and Zepbound, which contain tirzepatide, target both GLP-1 and GIP receptors.

Retatrutide remains an investigational drug and has not been approved by the US Food and Drug Administration (FDA) or other regulatory authorities.

Eli Lilly plans to submit the drug for FDA approval in early 2027. The company said detailed results from the trial would be presented at a future medical meeting and published in a peer-reviewed journal.

The hype around GLP-1 weight loss drugs keeps growing due to numerous new benefits as well as side effects that are discovered every other day. A recent study found that the risk of aortic aneurysm rupture is significantly less among GLP-1 users. The study was published in the Journal of Vascular Surgery.

GLP-1 receptor agonists is a a class of medicines that is widely used to treat type 2 diabetes and obesity. Users have reported substantial weight loss results with the help of these medicines like Ozempic, Mounjaro, Zepbound and others.

Now, researchers have found that people with abdominal aortic aneurysms who used GLP-1 drugs had a 46% lower risk of rupture over five years compared with those who did not use these medicines. This means that GLP-1 drugs may also have cardiovascular benefit apart from diabetes and obesity.

The study analysed health records from 123 healthcare organisations in the US. It is based on more than 412,000 people diagnosed with abdominal aortic aneurysms who underwent imaging surveillance every six months.

After matching patients based on factors like age, sex, diabetes, high blood pressure, smoking, heart disease and kidney disease, the researchers compared 13,722 GLP-1 receptor agonist users with an equal number of non-users.

GLP-1 Drugs Linked To Fewer Aortic Aneurysm Ruptures

Also read: ‘Godzilla’ Drug Retatrutide Reverses Sleep Apnea In 1 In 4 Diabetes Patients

After five years, aortic aneurysm rupture was recorded in about 1.6% of people taking GLP-1 drugs, compared to 2.4% of those who were not taking them.

The researchers reported a hazard ratio of 0.538, indicating a 46.2% lower risk of rupture among GLP-1 drug users after adjustment.

The difference was also observed at the two-year mark, when rupture occurred in 1.1% of GLP-1 users compared to 1.8% of non-users.

People taking GLP-1 drugs also had fewer elective aneurysm repairs. At five years, 2.1% of users underwent elective repair compared to 3% of non-users.

The study further found lower rates of major cardiovascular events like heart attacks, strokes and heart failure, as well as lower all-cause mortality among GLP-1 users.

What Is An Abdominal Aortic Aneurysm?

Also read: The Changing Obesity Treatment Landscape: Where Does Bariatric Surgery Fit in the Age of Weight-Loss Drugs?

An abdominal aortic aneurysm (AAA) occurs when a section of the aorta, the body's largest artery, becomes enlarged or bulges due to weakening of its wall. It develops in the part of the aorta that passes through the abdomen.

Many abdominal aortic aneurysms do not cause symptoms and are detected during tests. However, as the aneurysm enlarges, its risk of rupture increases.

A ruptured aneurysm is considered to be a medical emergency as it can cause severe internal bleeding. Symptoms may include sudden, severe abdominal or back pain, dizziness, fainting and a rapid heartbeat.

Smoking, older age, high blood pressure, atherosclerosis and a family history of aneurysms are among the risk factors.

GLP-1 Drugs & Lower Risk Of Aortic Aneurysm Rupture Risk

GLP-1 receptor agonists work by mimicking the naturally occurring GLP-1 hormone. They help regulate blood sugar by stimulating insulin release when glucose levels are high, slowing the emptying of stomach and reducing appetite.

Some of their effects may also impact blood vessel health. Abdominal aortic aneurysms develop through several processes, including inflammation, damage to vascular smooth muscle cells and changes in the proteins that maintain the artery wall.

GLP-1 drugs have shown anti-inflammatory and cardiovascular benefits in older research. The researchers suggest these effects may help explain the lower rates of aneurysm-related complications observed in the study.

The findings are promising but do not conclusively prove that GLP-1 medicines prevent aneurysm rupture. This was a retrospective observational study, meaning researchers examined existing health records rather than randomly assigning patients to receive the drugs.

One important limitation was that aneurysm size was not included among the matching variables. Since aneurysm size is a major determinant of rupture risk, differences between the groups could have impacted the findings.

When a woman misses her period, pregnancy is usually the first thing she thinks about. If that is ruled out, stress, weight changes or a hormonal imbalance may seem like the obvious explanations. But when periods become irregular or stop for several months, there may be more to the story.

In some women, these changes can also signal a risk to bone health. The menstrual cycle is controlled by a complex interaction between the brain and the ovaries. Oestrogen, one of the key hormones involved, is important not only for reproductive health but also for maintaining strong bones. It helps regulate the continuous process of bone breakdown and rebuilding.

When oestrogen levels remain low for a prolonged period, this balance can be disturbed, leading to a reduction in bone mineral density and, in some cases, an increased risk of fractures.

Menstrual health is not just about getting a period every month. It can offer important clues about what is happening elsewhere in the body.

Why Do Periods Sometimes Stop?

Also read: Why Do My Breasts Hurt Right Before My Period?

One possible cause is functional hypothalamic amenorrhoea, a condition in which the brain reduces the hormonal signals that stimulate the ovaries. It may occur when the body is under physical or emotional stress, particularly in the setting of inadequate food intake, rapid weight loss, excessive exercise or a combination of these factors.

In simple terms, the body may not be getting enough energy to support all its normal functions. Reproductive activity can slow down as a result. If this continues, the effects may extend beyond the menstrual cycle.

Low energy availability can affect hormones involved in bone formation and maintenance. Inadequate intake of protein, calcium and vitamin D may further compromise bone health.

The concern is particularly important in adolescents and young women, because these are the years when the body builds much of its peak bone mass. If this process is disrupted, they may not achieve their full bone-strength potential, which can have implications for bone health later in life. It can happen even when a woman is not underweight.

One common misconception is that only very thin women are at risk. In reality, a woman can have a seemingly healthy body weight and still not be eating enough to meet the demands of her daily activity.

A student under academic pressure may skip meals regularly. A working professional may combine long hours with restrictive eating, while a woman who exercises intensively may not increase her food intake to match her energy needs. In such situations, menstrual changes may be one of the first noticeable signs that something is wrong.

Persistent tiredness, declining exercise performance, poor recovery after workouts and recurrent bone or muscle injuries may provide additional clues.

These symptoms are easy to dismiss as the result of a busy lifestyle, but they deserve attention when they occur alongside irregular or absent periods.

Not Every Missed Period Has The Same Cause

Also read: Women With Endometriosis Are Earning Less, Reveals Study

Although inadequate energy intake and prolonged stress can affect menstruation, they are not the only explanations. Pregnancy must first be ruled out. Other possible causes include polycystic ovary syndrome (PCOS), thyroid disorders, raised prolactin levels, premature ovarian insufficiency, chronic illnesses and certain medications.

A woman should seek medical evaluation if her periods stop for three months without an explanation, if her cycles remain persistently irregular, or if menstrual changes are accompanied by significant weight loss, restrictive eating, excessive exercise, bone pain or a stress fracture.

The assessment usually begins with a detailed menstrual history and questions about diet, exercise, weight changes, stress and medication use. Depending on the findings, the doctor may recommend pregnancy testing, blood tests to assess thyroid function and reproductive hormones, prolactin levels and other investigations.

A bone mineral density scan may also be appropriate when periods have been absent for a prolonged period or when additional risk factors for bone loss are present.

Protecting Menstrual Health Also Means Protecting Bone Health

Treatment depends on the underlying cause. When inadequate energy availability is responsible, the priority is to restore a healthy balance between food intake, physical activity and recovery.

This may require nutritional guidance, changes to exercise routines and support for managing psychological stress. A gynaecologist may work with an endocrinologist, dietitian or mental-health professional, depending on the individual’s needs.

Adequate calcium, vitamin D and protein are important for bone health, but supplements alone cannot correct an ongoing energy deficit. Similarly, hormonal medication should not be prescribed simply to produce a period without first understanding why menstruation has stopped.

A menstrual cycle is more than a monthly reproductive event. Persistent changes can provide valuable clues about hormonal function, nutrition and overall health. Paying attention to these changes early can help identify underlying problems and, where necessary, protect bone health for the future.